CAR-T FOR B-CELL ALL
IN INDIA
B-cell Acute Lymphoblastic Leukaemia is CAR-T's strongest indication globally. NexCAR19 achieves 81% complete remission in both paediatric and adult B-ALL โ and India is the world's most cost-accessible country to receive it.
analyticsAt a Glance
- check_circleNexCAR19 B-ALL CR: 81% โ matching Kymriah ELIANA benchmark exactly
- check_circleTata Memorial Centre Mumbai: India's largest paediatric and adult B-ALL CAR-T programme
- check_circleAll-in cost ~$40,000โ55,000 USD including manufacturing and inpatient care
- check_circleHaplo-SCT consolidation available at TMC, AIIMS, CMC Vellore, and Narayana Health
Why B-ALL Is CAR-T's Strongest Indication
CD19 is uniformly expressed in B-cell ALL at diagnosis and in most relapses, making it an ideal CAR-T target. Globally, B-ALL shows the highest CR rates of any CAR-T indication โ and India's NexCAR19 matches the global benchmark.
โMRD-negative CR after NexCAR19 in B-ALL is the platform for cure โ not just remission.โ
Uniform CD19 in B-ALL
Unlike DLBCL where CD19 can be heterogeneous, B-ALL typically shows near-uniform CD19 expression at diagnosis. This makes virtually every B-ALL patient a potential CAR-T candidate โ the main selection criteria are performance status and organ function, not target antigen.
81% CR โ Matching the Global Benchmark
NexCAR19 achieved 81% complete remission in its B-ALL cohort (n=21) in the Nature Medicine 2024 publication. This exactly matches the 81% CR reported by Kymriah in the ELIANA trial (n=75) โ establishing NexCAR19 as clinically non-inferior in this setting.
Tata Memorial Centre โ India's Largest B-ALL Programme
TMC Mumbai runs India's highest-volume B-ALL CAR-T programme. The BMT unit (Dr. Navin Khattry) is the primary site for NexCAR19 in B-ALL and has experience in both paediatric and adult patients. TMC treats more paediatric ALL than any other Indian centre.
MRD-Negative CR: The Goal
The therapeutic goal in B-ALL is MRD (minimal residual disease)-negative complete remission โ confirmed by multiparameter flow cytometry or PCR. MRD negativity at Day 28 post-CAR-T is associated with durable responses and is the decision point for consolidative SCT in high-risk patients.
Eligibility Criteria for B-ALL CAR-T in India
Eligibility is assessed at the treating centre and covers molecular diagnosis, performance status, organ function, and prior treatment history.
Standard Inclusion Criteria
Confirmed B-cell ALL with CD19+ expression on pathology or flow cytometry. Relapsed/refractory after 2+ prior lines (or post-SCT relapse). Age: any (paediatric and adult both enrolled in NexCAR19). ECOG 0โ2. Adequate organ function. No active CNS leukaemia (leptomeningeal).
Ph+ ALL and Primary Induction Failure
Philadelphia chromosome-positive (Ph+) ALL patients can receive NexCAR19 โ typically continuing TKI therapy alongside or following CAR-T. Primary induction failure patients (no CR after first-line) are also considered at TMC on a case-by-case basis. MLL-rearranged ALL is treated like other high-risk B-ALL with CAR-T โ transplant consolidation.
B-ALL CAR-T Outcomes: NexCAR19 vs Global Benchmarks
NexCAR19 B-ALL data from the pivotal trial compared to Kymriah (ELIANA) โ the established global standard for paediatric/young adult B-ALL CAR-T.
Complete Remission โ B-ALL
- NexCAR19 B-ALL CR (India, 2024)81%
- Kymriah B-ALL CR (ELIANA, 2018)81%
CRS Safety โ B-ALL
- NexCAR19 Grade 3+ CRS6%
- Kymriah Grade 3+ CRS (ELIANA)22%
Post-CR Pathway: CAR-T to Haploidentical Transplant Consolidation
For high-risk B-ALL patients achieving MRD-negative CR after NexCAR19, consolidative haploidentical SCT within 3โ6 months is the recommended approach at Indian centres.
- 1
Day 28 Assessment โ MRD Status
Bone marrow aspirate with flow cytometry MRD assessment. MRD-negative CR confirms deep response and opens the transplant pathway.
- 2
High-Risk Stratification
High-risk features prompting SCT: Ph+/BCR-ABL, MLL-rearrangement, complex karyotype, primary induction failure, or prior SCT relapse.
- 3
Donor Identification
Haplo-SCT uses a half-matched family donor โ parent, sibling, or child. Available to nearly all patients. HLA typing initiated immediately after CR confirmation.
- 4
Transplant Conditioning
PT-Cy-based haploidentical conditioning regimen used at Indian centres (post-transplant cyclophosphamide protocol). Reduces GvHD without sacrificing GvL.
- 5
Haplo-SCT
Haploidentical stem cell transplant performed. Major programmes: TMC Mumbai, CMCH Vellore, AIIMS New Delhi, Manipal, Narayana Health.
B-ALL CAR-T Cost in India
- $30โ40KNexCAR19 ManufacturingManufacturing and product cost via ImmunoACT at Tata Memorial Centre.
- $40โ55KAll-In B-ALL CAR-TTotal including lymphodepletion, inpatient monitoring, and standard care.
- $25โ40KHaplo-SCT in IndiaHaploidentical stem cell transplant cost at Indian centres โ if required for consolidation.
- $65โ95KCAR-T + Haplo-SCT CombinedTotal cost for the complete CAR-T โ transplant pathway in India vs $700K+ in the USA.
More from the CAR-T India Resource Library
Explore NexCAR19 trial evidence, the transplant consolidation pathway, and access via CancerFax.
- CAR-T Cell Therapy in India โ Complete Guide
- NexCAR19 Clinical Trial Results: What the Pivotal Data Shows
- CAR-T as Bridge to Haploidentical Transplant for ALL in India
- The CAR-T Treatment Timeline in India: From Consultation to Discharge
- CRS Management at Indian CAR-T Centres: Tocilizumab Biosimilar Protocols
- How to Access CAR-T Cell Therapy in India via CancerFax
Frequently Asked Questions: B-ALL CAR-T in India
Is NexCAR19 safe for young children with B-ALL?
Yes. NexCAR19 was studied in both paediatric and adult B-ALL patients and is approved for all ages. Tata Memorial Centre has a dedicated paediatric haematology programme with experience managing CAR-T-associated toxicities in children. The 6% grade 3+ CRS rate in the pivotal trial is particularly reassuring in paediatric patients where intensive care requirements are more complex to manage.
Does every patient who achieves CR after NexCAR19 need a transplant?
No โ not all patients require consolidative transplant. Standard-risk patients in first CR with NexCAR19 may be monitored with MRD surveillance without proceeding to transplant. Consolidative haplo-SCT is primarily recommended for high-risk cytogenetics (Ph+, MLL-rearranged), prior SCT relapse, or patients with persistent MRD after CAR-T. The decision is made by the treating haematologist at Tata Memorial based on the individual risk profile.
Can adult ALL patients over 40 or 50 receive NexCAR19?
Yes. NexCAR19 is approved for adult B-ALL with no upper age limit โ unlike Kymriah, which is approved only to age 25 in the B-ALL indication. Adult ALL patients over 40 are evaluated on organ function and performance status rather than age. TMC Mumbai has enrolled adult patients in this age range in its programme. Older patients may face slightly higher toxicity risk, which is discussed during eligibility assessment.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Is Your B-ALL Case Eligible for CAR-T in India?
CancerFax reviews your haematology reports, MRD status, and prior treatment history to assess NexCAR19 eligibility and coordinate evaluation at Tata Memorial Centre or another approved Indian programme.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.